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CASE STUDY
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Abstract 
Introduction: Fibroblast growth factor 23 (FGF23) is secreted from bone and suppresses the absorption of phospho-
rus in renal proximal tubule and in intestinal tract. Therefore, the increase of serum FGF23 levels leads to hypophos-
phatemic situations. Tumor-induced osteomalacia is often induced by various tumors, but it is often difficult to 
identify the localization of tumor, because most of the FGF23-producing tumors are small and could be observed in 
any part of the body.
Case description: Here we report a case of elderly female subject with FGF23-related hypophosphatemic osteoma-
lacia who repeatedly experienced severe bone pain and fragility fracture in various parts of the body. Although we 
failed to identify the localization of tumor in this subject even with various examination, after starting phosphorus 
replacement therapy with relatively small amounts of calcium phosphate (1.5 g/day) (phosphorus content: 270 mg), 
hypophosphatemia was ameliorated and repeated bone pain was dramatically mitigated without any surgical 
operation.
Discussion and Evaluation: Even when we fail to identify the localization of tumor in subjects with FGF23-related 
hypophosphatemic osteomalacia, phosphorus replacement therapy for hypophosphatemia could reduce the bone 
pain.
Conclusions: We should be aware of the possibility that phosphorus replacement therapy exert marked beneficial 
effects for the reduction of bone pain in subjects with FGF23-related hypophosphatemic osteomalacia even when we 
fail to identify tumor localization.
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Background
It is known that fibroblast growth factor 23 (FGF23) 
is secreted from bone and suppresses the absorption 
of phosphorus in renal proximal tubule and in intesti-
nal tract. Therefore, the increase of serum FGF23 levels 
leads to hypophosphatemic situations (Bergwitz et  al. 
2011; Jonsson et  al. 2003; Yu and White 2005). Indeed, 
FGF23 is an etiology factor of autosomal dominant 
hypophosphatemic rickets (ADHR) and tumor-induced 
osteomalacia (Chong et  al. 2011, 2013). Tumor-induced 
osteomalacia is often induced by various tumors such as 
phosphaturic mesenchymal tumor and ovarian cancer. It 
is known that FDG-PET/CT and measurement of FGF23 
levels in limb with selective venous sampling are useful 
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to estimate the tumor localization and that, if possible, 
the resection of tumor is the best therapy for the dis-
ease. On the other hand, it is often difficult to identify the 
localization of tumor, since most of the FGF23-produc-
ing tumors are benign and small, and these tumors have 
potential to occur anywhere in the body. Here we report 
a case of elderly female subject with FGF23-related 
hypophosphatemic osteomalacia who often experienced 
severe bone pain and fragility fracture in various parts 
of the body. Since we failed to identify the localization of 
tumor in this subject even after various kinds of evalua-
tion, we started phosphorus replacement therapy for the 
treatment of hypophosphatemia. As the results, repeated 
bone pain in this subject was dramatically mitigated after 
the amelioration of hypophosphatemia by phosphorus 
replacement therapy.
Case presentation
In 2014, a 75-year-old female was hospitalized in our 
institution for the careful examination of whole body 
bone pain and fragility fracture. In 2012, she experienced 
fracture in proximal end of left tibia and left foot joint. 
At that time, bone density was as follows: lumbar spine 
YAM, 79%; left femur YAM, 58%. She was diagnosed as 
osteoporosis and started taking PTH formulation in local 
clinic. Furthermore, in 2013, she experienced femur frac-
ture on both sides and multiple rib fracture. At that time, 
bone density was as follows: lumbar spine YAM, 66%; left 
femur YAM, 59%. After then, she started taking bispho-
sphonates. In spite of such therapy, in 2014, she experi-
enced fracture in various parts of the body such as left 
pubis and left olecranon. After then, she started taking 
active vitamin D preparations. Finally, she was hospital-
ized in our institution for the careful examination of such 
frequent fracture in various parts of body.
On admission (August, 2014), her height was 142.5 cm 
and body weight was 44.7 kg (body mass index: 22.0 kg/
m2). Although her previous height was unknown, it 
seemed that her height became shorter apparently due to 
scoliosis and vertebral compression fracture. Blood pres-
sure was 132/84 mmHg and heart rate was 80 bpm. Body 
temperature was 36.9  °C. Her consciousness was clear, 
but she was under bedrest state all day due to severe bone 
pain throughout the whole body and she had a lot of diffi-
culties even when she tried to turn over in bed. Although 
there was thoracic deformity, respiratory and heart 
sound was normal. In addition, there was no abnormality 
in abdomen. Table 1 shows the clinical characteristics of 
this subject on admission. Hypophosphatemia (1.5  mg/
dL) and hypocalcemia (8.1 mg/dL) (8.3 mg/dL after cor-
rection with serum albumin level) were observed. ALP 
level was high (855 U/L), and BAP (bone-type ALP) level 
was as high as 88.2  μg/L (normal range 3.8–22.6  μg/L). 
Serum FGF23 level was also as high as 275 pg/mL (nor-
mal range: 10–50  pg/mL). As shown in Table  1, vari-
ous tumor marker levels all of which we measured were 
within normal range except for the slight increase of SCC 
level. As shown in Fig. 1a, in chest X-ray, there were rem-
nants of multiple rib fracture, marked deformation of the 
thorax, scoliosis and cardiomegaly. In bone scintigraphy, 
abnormal accumulation was observed in ribs on both 
sides and limb joints (Fig. 1b). These are the findings after 
multiple fractures in the body. In computer tomography 
(CT), there was sciatic fracture on both sides, multiple 
rib fracture, vertebral compression fracture and marked 
deformation in the thorax (Fig. 1c). Neoplastic lesion was 
not observed in bone and soft tissues. There was local-
ized frosted glass shade in upper right lung field. In FDG-
PET/CT, there was no abnormal accumulation in the 
whole body, although slight accumulation was observed 
in thoracolumbar spine and upper limb joint which was 
presumably due to arthritis (Fig.  1d). Furthermore, we 
performed selective venous sampling and measured 
serum FGF23 levels in various parts of limb, but there 
was no marked difference in FGF23 levels among vari-
ous parts of limb as follows: elbow vein, 331 pg/mL (left), 
326 pg/mL (right), femoral vein, 299 pg/mL (left), 295 pg/
mL (right).
Since we failed to identify the localization of tumor in 
this subject even with various kind of measurements, we 
had no choice but to depend on drug therapy and started 
phosphorus replacement therapy for hypophosphatemia. 
On September, 2014, we started using calcium phosphate 
for the treatment of hypophosphatemia in addition to 
active vitamin D preparations. We used relatively small 
amounts of calcium phosphate (1.5  g/day) (phosphorus 
content: 270  mg) in order to avoid the appearance of 
some side effects in this elderly subject. Such treatment, 
however, exerted marked beneficial effects in this subject. 
Hypophosphatemia was significantly ameliorated from 
1.5 to 2.5  mg/dL. After discharge from our institution, 
serum phosphorus levels were within normal range and 
there was no recurrence of hypophosphatemia with the 
same amounts of calcium phosphate (1.5  g/day). Serum 
phosphorus level on March and July in 2015 was 2.5 and 
2.7  mg/dL, respectively. Serum calcium levels were also 
within normal range and there was no recurrence of 
hypocalcemia. Serum calcium level on March and July 
in 2015 was 9.1 mg/dL (8.9 mg/dL after correction with 
serum albumin level) and 9.4 mg/dL (9.1 mg/dL after the 
correction), respectively. ALP level gradually decreased 
after the discharge, but it did not reach the normal range. 
ALP levels on March and July in 2015 was 654 U/L and 
591 U/L, respectively. Since this patient hesitated to have 
an examination about bone density after starting calcium 
phosphate, we failed to obtain the follow-up data about 
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this point after starting the therapy. We think, however, 
that it would be better to examine the alteration of bone 
density after starting the therapy in such cases.
About one month after the treatment, bone pain was 
decreased by half, and about two months later, she did 
not feel at all any pain at rest. Finally, about three months 
later, she became able to stand up without any difficulties 
and perform a light labor. It is noted here there was no 
special treatment for this subject except for the phospho-
rus replacement therapy.
Taken together, bone pain was dramatically reduced 
after phosphorus replacement therapy in an elder 
female subject with FGF23-related hypophosphatemic 
osteomalacia.
Conclusion and discussion
In this report, we showed a case of elder female subject 
with FGF23-related hypophosphatemic osteomalacia. 
She experienced severe bone pain and fragility fracture 
very frequently in various parts of the body, but after 
starting phosphorus replacement therapy for hypophos-
phatemia, marked beneficial effects were obtained. After 
the phosphorus replacement therapy, hypophosphatemia 
was significantly ameliorated which was accompanied by 
the dramatic reduction of bone pain.
The absorption of phosphorus in renal proximal 
tubule is one of the most important determinants for 
serum phosphorus concentration. FGF23 suppresses 
such absorption of phosphorus in renal proximal tubule 
reduces, which leads to reduction of serum phospho-
rous levels. In addition, FGF23 functions to suppress 
the absorption of phosphorus in intestinal tract. Such 
suppression of phosphorus absorption leads to the 
development of hypophosphatemic diseases such as 
tumor-induced osteomalacia. In general, the resection of 
the tumor is the best way for tumor-induced osteomala-
cia, but in this case we failed to identify the localization 
of tumor even with various kind of evaluation. Even in 
such situations, however, phosphorus replacement ther-
apy for hypophosphatemia markedly reduced the bone 
pain. Therefore, even when we fail to identify tumor 
localization, we should start phosphorus replacement 
therapy. In addition, only small amounts of calcium phos-
phate (1.5  g/day) (phosphorus content: 270  mg) were 
used for this subject in order to avoid the appearance of 
side effects, but bone pain which we failed to suppress 
with any treatment was dramatically mitigated by the 
phosphorus replacement therapy, and we think that the 
amelioration of hypophosphatemia with this treatment 
would lead to the prevention of further fracture.
Table 1 Clinical characteristics of this subject on admission
WBC 5350/μL CK 38 U/L Whole PTH 25.6 pg/mL
Neu 66.6% CRP 0.08 mg/dL PTHrP ≤1.0 pmol/L
Lym 25.9% PBS 83 mg/dL 1,25(OH)2D3 38.9 pg/mL
Mon 5.1% HbA1c 5.3% 25(OH)D 7 ng/mL
Eo 2.2% LDL-chol 95 mg/dL ACTH 27.8 pg/mL
Bas 0.2% HDL-chol 41 mg/dL Cortisol 6.6 μg/dL
RBC 405 × 104/μL TG 118 mg/dL DHEA-S 74 μg/dL
Hb 12.8/μL TSH 0.66 μU/mL FGF23 275 pg/mL
Ht 37.7/μL FT4 1.05 ng/dL Osteocalcin 7.6 ng/mL
plt 18.5 × 104/μL IgG 931 mg/dL Serum NTx 22.8 nmol 
BCE/L
TP 6.1 g/dL IgA 141.6 mg/dL TRACP-5b 357 mU/dL
Alb 3.8 g/dL IgM 48.7 mg/dL BAP 88.2 μg/L
T-bil 0.3 mg/dL Na 141 mEq/L ucOC 1.93 ng/mL
AST 22 U/L K 3.9 mEq/L Intact PINP 96.5 μg/L
ALT 17 U/L IP 1.5 mg/dL CEA 1.5 ng/mL
γGTP 50 U/L Ca 8.1 mg/dL CA19-9 7.9 U/mL
ALP 855 U/L Corrected Ca 8.3 mg/dL CA125 8 U/mL
LDH 166 U/L Urinary Cre 21 mg/dL SLX 20.0 U/mL
ChE 295 U/L Urinary P 5.9 mg/dL AFP 2.4 ng/mL
Crn 0.37 mg/dL Urinary Ca 9.9 mg/dL SCC 1.9 ng/mL
BUN 11 mg/dL FECa 4.46% CYFRA 1.8 ng/mL
UA 4.8 mg/dL Tmp/GFR 1.40 mg/dL ProGRP 45.6 pg/mL
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Fig. 1 a Chest X-ray. There are remnants of multiple rib fracture, marked deformation of the thorax, scoliosis and cardiomegaly. b Bone scintigra-
phy. Abnormal accumulation is observed in ribs on both sides, limb joints. These are the findings after multiple fractures in the body. c Computer 
tomography (CT). There is sciatic fracture on both sides, multiple rib fracture, vertebral compression fracture and marked deformation in the thorax. 
Neoplastic lesion is not observed in bone and soft tissues. There is localized frosted glass shade in upper right lung field. d FDG-PET/CT. There is no 
abnormal accumulation in the whole body, although slight accumulation is observed in thoracolumbar spine and upper limb joint probably due to 
arthritis
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It is well know that bone pain could be due to bone 
metastasis of various kinds of malignant diseases. Espe-
cially, lung cancer, breast cancer and melanoma often 
bring out bone metastasis. However, she had no symp-
toms and no findings in CT and PET-CT with which 
we should suspect that she had lung cancer. In addition, 
she had no symptom in breast and there was no specific 
observation with which we should suspect that she had 
breast cancer. There was no specific findings in periph-
eral blood test with which we should suspect that she had 
some hematological disease, although we did not perform 
bone puncture. Furthermore, there was no specific find-
ings in her skin in the whole body with which we should 
suspect that she had some disease such as melanoma.
There is a limitation in this study. Hospitalization 
period of this subject was relatively short (12  days) 
(August 12–23, 2014) due to the convenience of this 
subject. In addition, after the reduction of bone pain, 
this subject denied to have various examination. There-
fore, although we confirmed that the reduction of bone 
pain was closely associated with the amelioration of 
hypophosphatemia, we failed to examine whether the 
reduction of bone pain is associated with various objec-
tive indicators such as grip strength and bone density. 
We think we should have performed such examination so 
that we could more objectively show the benefit of small 
amounts of phosphorus replacement therapy.
Taken together, we should be aware of the possibility 
that relatively small amounts of calcium phosphate would 
be enough to reduce the symptom of bone pain and pos-
sibly lead to the prevention of fragility fracture especially 
in elderly subjects as observed in this subject. We think 
that the findings in this report would be useful from the 
clinical point of view.
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